TS-ONE Dosage/Direction for Use

The standard doses in the table as follows are the recommended initial dose for adults according to body surface area. (See Table 6.)

Click on icon to see table/diagram/image

The initial dose can be decreased according to the patient's tolerance to the medication. The reduction of dose may be done in 10 mg intervals, with a lower limit of 40 mg.
Monotherapy: TS-ONE should be administered twice daily, after breakfast and after the evening meal, for 28 consecutive days, followed by a 14-day rest. This is regarded as one course of the regimen.
Combination Therapy: Non-Small Cell Lung Cancer: TS-ONE is recommended to be administered twice daily, after meals, for 14 consecutive days, in combination with carboplatin (AUC 5) on Day 1. This treatment is repeated every 3 weeks.
Colorectal Cancer: For 1^st line of treatment, TS-ONE is recommended to be administered twice daily, after meals, for 14 consecutive days, in combination with oxaliplatin 130 mg/m² on Day 1 as a 2 hour intravenous infusion. This treatment is repeated every 3 weeks.
For 2^nd line of treatment, TS-ONE is recommended to be administered twice daily, after meals, from Day 1 to 14, in combination with irinotecan 125 mg/m² on Days 1 and 15. This treatment is repeated every 4 weeks.
Gastric Cancer: TS-ONE is recommended to be administered twice daily, after meals, for 21 consecutive days and 60 mg/m² intravenous infusion of cisplatin on Day 8, followed by a 14 days rest. This treatment is repeated every 5 weeks.
Use in the Elderly: Since elderly patients often have decreased physiological functions, TS-ONE should be administered with care.
Pediatric Use: The efficacy and safety of TS-ONE in children and adolescents have not been established. Therefore, use in this patient population is not recommended.